JP2022065034A5 - - Google Patents

Download PDF

Info

Publication number
JP2022065034A5
JP2022065034A5 JP2022017693A JP2022017693A JP2022065034A5 JP 2022065034 A5 JP2022065034 A5 JP 2022065034A5 JP 2022017693 A JP2022017693 A JP 2022017693A JP 2022017693 A JP2022017693 A JP 2022017693A JP 2022065034 A5 JP2022065034 A5 JP 2022065034A5
Authority
JP
Japan
Prior art keywords
nucleic acid
strain
poxvirus
chimeric poxvirus
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022017693A
Other languages
English (en)
Japanese (ja)
Other versions
JP7395628B2 (ja
JP2022065034A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/046163 external-priority patent/WO2018031694A1/en
Application filed filed Critical
Publication of JP2022065034A publication Critical patent/JP2022065034A/ja
Publication of JP2022065034A5 publication Critical patent/JP2022065034A5/ja
Priority to JP2023200433A priority Critical patent/JP7631485B2/ja
Application granted granted Critical
Publication of JP7395628B2 publication Critical patent/JP7395628B2/ja
Priority to JP2025016649A priority patent/JP2025072482A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022017693A 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用 Active JP7395628B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023200433A JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof
JP2019507161A JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019507161A Division JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023200433A Division JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2022065034A JP2022065034A (ja) 2022-04-26
JP2022065034A5 true JP2022065034A5 (https=) 2022-08-19
JP7395628B2 JP7395628B2 (ja) 2023-12-11

Family

ID=61163330

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Country Status (10)

Country Link
US (2) US12084687B2 (https=)
EP (1) EP3497209A4 (https=)
JP (4) JP7023929B2 (https=)
KR (3) KR20230113832A (https=)
CN (3) CN118853594A (https=)
AU (2) AU2017311380A1 (https=)
CA (1) CA3033512A1 (https=)
MX (1) MX2019001672A (https=)
RU (2) RU2757002C2 (https=)
WO (1) WO2018031694A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
KR20230113832A (ko) * 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
WO2019033030A1 (en) * 2017-08-11 2019-02-14 City Of Hope ONCOLYTIC VIRUS EXPRESSING A CAR-T CELL TARGET AND USES THEREOF
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
CA3093093A1 (en) * 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
US20260049291A1 (en) 2022-08-18 2026-02-19 Transgene Chimeric poxviruses
WO2024245722A2 (en) * 2023-05-26 2024-12-05 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
EP1268763A2 (en) 2000-03-28 2003-01-02 University Of Rochester Methods of producing a library and methods of selecting polynucleotides
CA2501168A1 (en) * 2002-11-25 2004-06-10 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters
ATE420160T1 (de) * 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
HRP20150360T1 (hr) * 2007-11-19 2015-05-08 Transgene Sa Poksvirusni onkolitiäśki vektori
US20130071430A1 (en) * 2010-04-09 2013-03-21 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
JP2015520754A (ja) 2012-05-18 2015-07-23 オタゴ イノベーション リミテッド 創傷治癒のための組合せ治療および組成物
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR20230113832A (ko) * 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2022065034A5 (https=)
JP2025072482A5 (https=)
JP2019524131A5 (https=)
JP2024026191A5 (https=)
RU2021128158A (ru) Композиции химерного поксвируса и их применение
KR101994953B1 (ko) 침입성 dna 바이러스에 대해 식물 내성을 강화하는 방법
Pratap et al. Molecular characterization and infectivity of a Tomato leaf curl New Delhi virus variant associated with newly emerging yellow mosaic disease of eggplant in India
Yang et al. Pervasive initiation and 3′-end formation of poxvirus postreplicative RNAs
JPH03503482A (ja) ポックスウイルスベクター
Mathew et al. The extracellular domain of vaccinia virus protein B5R affects plaque phenotype, extracellular enveloped virus release, and intracellular actin tail formation
JP2013507935A5 (https=)
CN110607320B (zh) 一种植物基因组定向碱基编辑骨架载体及其应用
Jeong et al. Characterization of the DNA nucleotide sequences in the genome of red sea bream iridoviruses isolated in Korea
CN113061586B (zh) 表达血清8型禽腺病毒纤突蛋白重组血清4型禽腺病毒以及制备方法
Li et al. Characterization of silencing suppressor p24 of Grapevine leafroll‐associated virus 2
JP2024520868A5 (https=)
CN102787125A (zh) 一种构建tale重复序列的方法
MX2024002641A (es) Uso de micro ácido ribonucleico (arn) para la regulación por disminución de la expresión de transgenes citotóxicos mediante el virus vaccinia ankara modificado (mva).
JP2021534818A5 (https=)
CN105779444A (zh) 一种提高芽孢杆菌蛋白表达量的串联启动子
RU2019112725A (ru) Композиции и способы для повышения стабильности трансгенов в поксвирусах
Gorzkiewicz et al. The role of glycosylation patterns of viral glycoproteins and cell entry receptors in arenavirus infection.
Kumari et al. Cucumber RDR1s and cucumber mosaic virus suppressor protein 2b association directs host defence in cucumber plants
Margaria et al. Comparison of small RNA profiles in Nicotiana benthamiana and Solanum lycopersicum infected by polygonum ringspot tospovirus reveals host-specific responses to viral infection
Senkevich et al. Nucleotide sequence of XhoI O fragment of ectromelia virus DNA reveals significant differences from vaccinia virus